Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety of Lanreotide and Metformin for Patients with Advanced Gastrointestinal or Lung Carcinoids

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the safety of a treatment combination for patients with advanced forms of certain types of tumors known as gastrointestinal or lung carcinoids. These are rare types of tumors that develop in the digestive system or lungs. The treatment being tested includes two medications: Lanreotide, which is given as an injection, and Metformin, which is taken as a tablet. Lanreotide is a type of medication that helps to control the growth of certain tumors, while Metformin is commonly used to manage blood sugar levels in people with diabetes.

The purpose of this study is to evaluate how safe it is to use Lanreotide in combination with Metformin in patients with these specific types of tumors. Participants in the study will receive both medications and will be monitored for any side effects or changes in their condition. The study is designed to observe how the body responds to this combination of treatments over a period of time. Participants will receive regular check-ups, including physical exams and laboratory tests, to ensure their safety and to gather information about the treatment's effects.

This study is open-label, meaning that both the participants and the researchers know which treatments are being administered. It is a pilot study, which means it is an initial, smaller-scale study to gather preliminary data. The study will help researchers understand the potential benefits and risks of using Lanreotide and Metformin together in treating advanced gastrointestinal or lung carcinoids. The information gathered from this study may contribute to future research and treatment options for these types of tumors.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current health status.

    Blood tests are performed to check various health indicators such as neutrophil counts, platelet counts, hemoglobin levels, and liver function tests.

    A physical examination is conducted to assess overall health and any specific symptoms related to the condition being studied.

  2. Step 2

    Treatment initiation

    The treatment phase begins with the administration of lanreotide and metformin.

    Lanreotide is given as an intramuscular injection at a dose of 120 mg. This is a solution for injection provided in a pre-filled syringe.

    Metformin is taken orally in the form of film-coated tablets, with a dosage of 850 mg per tablet.

  3. Step 3

    Ongoing treatment and monitoring

    The treatment continues with regular administration of the medications as prescribed.

    Regular monitoring is conducted to evaluate the safety and effectiveness of the treatment. This includes physical examinations, laboratory tests, and cardiologic assessments.

    The study aims to assess any adverse effects (AEs) or serious adverse effects (SAEs) that may occur during the treatment period.

  4. Step 4

    Evaluation of treatment efficacy

    The efficacy of the treatment is evaluated by measuring the time to progression (TTP) of the disease. This is defined as the time from the first administration of the study drugs to the first sign of disease progression or tumor-related death.

    The study also evaluates the symptomatic response to the treatment, assessing any changes in symptoms experienced by the patient.

  5. Step 5

    Completion of study participation

    Upon completion of the study period, a final assessment is conducted to evaluate the overall health status and any long-term effects of the treatment.

    Patients are advised on any necessary follow-up care or monitoring after the study concludes.

Who can join the trial?

25 criteria

  • Adult patients, both male and female, who are older than 18 years.
  • Blood tests must show:
    • Neutrophils (a type of white blood cell) count greater than 1.5 x 103 per liter.
    • Platelet count greater than 100 x 103 per liter.
    • Hemoglobin (a protein in red blood cells) greater than 9 grams per deciliter.
    • Total Bilirubin (a substance made by the liver) less than 1.5 times the normal upper limit.
    • AST and ALT (liver enzymes) less than 2.5 times the normal upper limit.
    • Alkaline phosphatase (an enzyme related to the liver) less than 2.5 times the normal upper limit.
    • Serum creatinine (a waste product in the blood) less than 1.5 milligrams per deciliter.
    • CCr (creatinine clearance, a measure of kidney function) equal to or greater than 60 milliliters per minute.
    • **ECOG performance status** of 2 or less, which is a scale to assess how a patient's disease is progressing and how the disease affects their daily living abilities.
    • Life expectancy of more than 12 months.
    • Must provide written informed consent to participate in the study.
    • Female participants who can have children must use a medically accepted method of birth control and agree to continue using it during the study and for at least 60 days after the study. Acceptable methods include:
      • Double barrier method (e.g., condom and diaphragm).
      • Spermicide.
      • Intrauterine device (IUD).
      • Steroidal contraceptive (e.g., oral, transdermal, implanted, injected) with a barrier method.
      • Male participants with female partners who can have children must use a medically accepted method of birth control and agree to continue using it during the study and for 60 days after the study.
      • Patients with advanced disease that cannot be surgically removed, as evaluated by a specialized medical team.
      • Patients with a confirmed diagnosis of advanced well-differentiated (G1 and G2) gastrointestinal or lung carcinoids, according to the latest WHO Classification criteria for neuroendocrine tumors (NET).
      • Tumor tissue must be available for analysis.
      • Measurable disease and disease progression within 6 months before joining the study, confirmed by appropriate imaging tests.
      • Patients who have previously received treatment with surgery, chemotherapy, somatostatin analogues, m-TOR inhibitors, or other systemic cancer therapies.
      • Patients with functioning or non-functioning NETs.
      • Patients with type-2 diabetes or normal blood sugar levels.
      • Documented uptake of Octreoscan/PET Ga or IHC stain of SSTR2 receptor within 6 months before joining the study.

Who cannot join the trial?

1 criterion

  • Patients with **advanced progressive gastro-intestinal or lung carcinoids** cannot participate. These are types of tumors that grow in the digestive system or lungs and are getting worse over time.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Lanreotide

    is a medication used in this trial to help manage symptoms and slow the growth of certain types of tumors, specifically well-differentiated gastro-intestinal or lung carcinoids. It works by mimicking a natural hormone in the body that can inhibit the release of other hormones and growth factors that may contribute to tumor growth.

  • Metformin

    is a medication commonly used to manage blood sugar levels in people with type 2 diabetes. In this trial, it is being used in combination with Lanreotide to explore its potential benefits in treating patients with advanced carcinoid tumors. Metformin may have effects on tumor growth and metabolism, which is why it is being studied in this context.

What is already known about the treatment

  • Lanreotide

    Lanreotide is administered as an injection under the skin, typically in the form of a pre-filled syringe. It is currently being studied in clinical trials for its safety and effectiveness in combination with Metformin for treating advanced progressive gastrointestinal or lung carcinoids. The medication is primarily used to manage symptoms associated with certain types of tumors by inhibiting the release of growth hormones. Lanreotide belongs to the pharmacological class of somatostatin analogs, which work by mimicking the action of the natural hormone somatostatin to reduce hormone secretion.

  • Metformin

    Metformin is taken orally in tablet form and is widely used in medicine, primarily for managing type 2 diabetes. In the context of clinical trials, it is being evaluated for its safety and potential benefits when used alongside Lanreotide for treating advanced progressive gastrointestinal or lung carcinoids. Metformin works by decreasing glucose production in the liver and improving the body's sensitivity to insulin. It is classified as a biguanide, a type of medication that helps control blood sugar levels.

Investigated diseases

  • Gastrointestinal Carcinoid Tumors

    These are a type of neuroendocrine tumor that typically develops in the digestive tract, including the stomach, intestines, and rectum. They grow slowly and may not cause symptoms initially, but as they progress, they can lead to abdominal pain, diarrhea, and flushing. Over time, these tumors can spread to other parts of the body, such as the liver, causing more severe symptoms. The progression of the disease can vary, with some tumors remaining stable for years while others grow more rapidly.

  • Lung Carcinoid Tumors

    These are rare, slow-growing tumors that originate in the lungs and are a type of neuroendocrine tumor. They often do not cause symptoms in the early stages, but as they grow, they can lead to coughing, wheezing, and shortness of breath. In some cases, they may produce hormones that cause symptoms like flushing or diarrhea. The progression of lung carcinoid tumors can vary, with some remaining localized while others may spread to lymph nodes or other organs.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513200-34-00Estimated enrolment20 patientsSponsorFondazione IRCCS Istituto Nazionale Dei Tumori

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).